SCHEMBL4375997

SCHEMBL4375997

CCC(CC)N1CCN(C(=O)c2cccc(Oc3ccccc3)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
POLB P06746 1/20 0.65
MAPT P10636 2/20 0.60
HTT P42858 2/20 0.60
CRHBP P24387 1/20 0.60
CRHR2 Q13324 1/20 0.60
GAA P10253 2/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
PARP10 Q53GL7 6/20 0.56
PARP14 Q460N5 4/20 0.56
HRH3 Q9Y5N1 2/20 0.54
MGLL Q99685 3/20 0.50
FAAH O00519 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4382856 0.99 MEN1 (0.64) MEN1KMT2APOLBMAPTHTT
SCHEMBL4384195 0.84 MEN1 (0.70) MEN1KMT2APOLBMAPTKDM4E
SCHEMBL4377566 0.83 HRH3 (0.74) MEN1KMT2APOLBHTTGAA
Hydrochloric Acid SCHEMBL4382264 0.82 MEN1 (0.68) MEN1KMT2APOLBMAPTKDM4E
Hydrochloric Acid SCHEMBL4383232 0.82 HRH3 (0.75) MEN1KMT2APOLBHTTGAA
SCHEMBL4384315 0.76 KMT2A (0.62) MEN1KMT2APOLBHTTALDH1A1
SCHEMBL3455749 0.75 KMT2A (0.60) MEN1KMT2APOLBMAPTHTT
SCHEMBL6532498 0.75 PARP10 (0.82) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL17404521 0.75 PARP10 (0.60) MEN1KMT2AMAPTHTTCRHBP
SCHEMBL13826101 0.75 PARP10 (0.58) MEN1KMT2AMAPTHTTCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 MEN1 2570/4885KMT2A 295/4885POLB 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.